• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    An evaluation of concurrent chemoradiotherapy practice for locally advanced non-small cell lung cancer (NSCLC) in a single centre institution

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Beardsworth, S.
    Bayman, Neil A
    Coote, Joanna H
    Cove-Smith, Laura
    Faivre-Finn, Corinne
    Harris, Maggie A
    Salem, Ahmed
    Sheikh, Hamid Y
    Taylor, Paul
    Woolf, David K
    Fenemore, Jackie
    Chan, Clara
    Show allShow less
    Affiliation
    Faculty of Biology, Medicine and Health, University of Manchester, Manchester,
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Introduction: The standard treatment for unresectable stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CTRT). However, only a minority of patients receive CTRT due to poor performance status (PS) or co-morbidities. Carboplatin/ paclitaxel (CP) was introduced in our centre in 2017 as an alternative to cisplatin/etoposide (CE) to increase the number of patients receiving CTRT. We compare toxicity and outcomes between two chemotherapy regimens (CE and CP) in our centre. Methods: A retrospective audit was undertaken. Demographics, baseline health, treatment toxicity, response, adjuvant durvalumab use and survival were collected for patients treated with CP and CE 2018-2019. Toxicity and outcome in patients were compared (CP v CE). Results: 106 patients were treated with concurrent CTRT 2018-2019 (CP n=20, CE n=86). Patients selected for CP mostly either had impaired renal function (n=6 (30%)), a pre-existing hearing problem (n=5 (25%)) or underlying cardiovascular co-morbidity (n=5 (25%)). Baseline demographics, eGFR and proportion receiving durvalumab were well matched (Table 1). More patients receiving CP were PS 2 (CP 15% v CE 1.2%, p=0.02). CE was associated with greater G3/G4 side effects (CP 30% v CE 60.5%, p=0.01) however CP was associated with a higher incidence of G1/2 toxicity (p< 0.05) and chemotherapy dose reduction/omission (CP 15% v CE 3%, p=0.05). There was no significant difference in the progression free (13 v 17 months, p=0.3) or 1-year overall survival (65% v 79%, p=0.24) Conclusion: The introduction of CP and durvalumab have helped facilitate increased numbers of patients receiving CTRT treatment. CE had a higher level of G3/4 toxicity and patients treated with CP had greater levels of G1/2 toxicity and reduced dose intensity. There was no overall difference in survival between the groups suggesting that both regimens should be considered in patients with stage III NSCLC.
    Citation
    Beardsworth S, Bayman N, Coote J, Cove-Smith L, Faivre-Finn C, Harris M, et al. An evaluation of concurrent chemoradiotherapy practice for locally advanced non-small cell lung cancer (NSCLC) in a single centre institution. Vol. 165, Lung Cancer. Elsevier BV; 2022. p. S51–2.
    Journal
    Lung Cancer
    URI
    http://hdl.handle.net/10541/625228
    DOI
    10.1016/S0169-5002(22)00157-X
    Additional Links
    https://dx.doi.org/10.1016/S0169-5002(22)00157-X
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/S0169-5002(22)00157-X
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.